EP1255744A1 - Substituierte phenylamidine, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung - Google Patents

Substituierte phenylamidine, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung

Info

Publication number
EP1255744A1
EP1255744A1 EP01903646A EP01903646A EP1255744A1 EP 1255744 A1 EP1255744 A1 EP 1255744A1 EP 01903646 A EP01903646 A EP 01903646A EP 01903646 A EP01903646 A EP 01903646A EP 1255744 A1 EP1255744 A1 EP 1255744A1
Authority
EP
European Patent Office
Prior art keywords
group
alkyl
general formula
phenyl
salts
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP01903646A
Other languages
German (de)
English (en)
French (fr)
Inventor
Frank Himmelsbach
Brian Guth
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim Pharma GmbH and Co KG
Original Assignee
Boehringer Ingelheim Pharma GmbH and Co KG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharma GmbH and Co KG filed Critical Boehringer Ingelheim Pharma GmbH and Co KG
Publication of EP1255744A1 publication Critical patent/EP1255744A1/de
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/145—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/15—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Definitions

  • Phenylamidines of the general formula fall within the scope of protection of WO 96/33970
  • R 1 is a C 1 _ 4 alkyloxycarbonyl group, an aryl C 1 . 3- alkyloxycarbonyl group or a group of the formula
  • R a is a hydrogen atom or an alkyl group
  • Rk represents an alkyl group or a 3- to 7-membered cycloalkyl group, meaning that no such compound is described expressly verbis in this laid-open specification.
  • R 6 is a hydroxy, , Arylcarbonyl or
  • R 7 is a hydrogen atom, a , C 4 . 7- Cycloalkyl, phenyl-C - ⁇ - alkyl or R a -CO-OCHR 9 group, in which
  • R 8 is a C 1-4 alkyl, C 1-4 alkoxy, C 3 . 7- cycloalkyl or C 4-7 -cycloalkoxy group and
  • R 9 represents a hydrogen atom or a C 1-4 alkyl group
  • tautomers, their stereoisomers and their salts in particular their physiologically tolerable salts with inorganic or organic acids or bases, also have valuable pharmacological properties, preferably antithrombotic effects.
  • aryl moieties mentioned in the definition of the abovementioned radicals are to be understood as meaning a phenyl group which can in each case be monosubstituted by R 10 , mono-, di- or trisubstituted by R X1 or monosubstituted by R 10 and additionally mono- or disubstituted by R ⁇ l , where the substituents can be the same or different and
  • R 10 is a cyano, carboxy, C ⁇ alkoxycarbonyl, aminocarbonyl, C ⁇ alkylaminocarbonyl, di (C ⁇ alkyl) aminocarbonyl, C ⁇ alkylsulfenyl, C ⁇ alkylsulfinyl, C ⁇ -alkylsulfonyl-, hydroxy-, C ⁇ -alkylsulfonyloxy-, trifluoromethyloxy-, nitro-, amino-, C ⁇ -alkylamino-, di- (C ⁇ -alkyl) -amino-, C - ⁇ - alkyl- carbonylamino-, N- (C 1-4 -alkyl) -C - ⁇ - alkylcarbonylamino-, C 1.4 -alkylsulfonylamino-, N- (C ⁇ -alkyl) -C ⁇ -alkylsulf
  • R__ is a fluorine, chlorine, bromine or iodine atom, a C 1-4 alkyl, trifluoromethyl or C ⁇ alkoxy group or
  • R 117 two radicals R 117, if they are bonded to adjacent carbon atoms, together represent a C 3 _5 ⁇ alkylene, methylenedioxy or 1, 3-butadien-1, 4-ylene group.
  • the present invention relates to the compounds of the general formula I above, their tautomers, their stereoisomers and their salts, in particular their physiologically tolerable salts with inorganic or organic acids or bases, medicaments containing these compounds, their use and process for their preparation.
  • the substituted amidino group is in the 4-position, in particular those compounds in which
  • R 6 is a hydroxy, C 1-18 alkyloxycarbonyl, phenylcarbonyl or phenyl C x . 4- alkyloxycarbonyl group and
  • R 7 is a hydrogen atom, a , C s . 7 denotes cycloalkyl or phenyl-C 1-4 alkyl group, wherein the above-mentioned phenyl parts can each be mono- or disubstituted by R 11 , the substituents being the same or different, and
  • R X1 represents a fluorine, chlorine or bromine atom, a C - ⁇ - alkyl, trifluoromethyl or C 1 _ 2 alkoxy group, a their tautomers, their stereoisomers and their salts.
  • R 6 is a hydroxy, C 1-12 alkyloxycarbonyl, phenylcarbonyl or phenylC 1-2 alkyloxycarbonyl group and
  • R 7 represents a C ⁇ g alkyl or C s. 7 -cycloalkyl group
  • R s is a hydroxy, C 5-12 alkyloxycarbonyl, phenylcarbonyl or benzyloxycarbonyl group and
  • R 7 is a C x . 4 alkyl or C 5 . s mean cycloalkyl group
  • the new compounds of the general formula I are obtained, for example, by the following process:
  • R 7 is defined as mentioned at the beginning
  • R 6 ' with the exception of the hydroxy group, has the meanings mentioned for R s and Z- L is a nucleofugic leaving group such as a halogen atom, for example a chlorine atom, or, if R s ' represents an arylcarbonyl group, a hydroxyl group.
  • the reaction is preferably carried out in a solvent such as acetone, methylene chloride, tetrahydrofuran, toluene, dioxane or acetonitrile, optionally in the presence of an inorganic or a tertiary organic base, preferably at temperatures between -20 ° C. and the boiling point of the solvent used.
  • a solvent such as acetone, methylene chloride, tetrahydrofuran, toluene, dioxane or acetonitrile
  • reaction with a compound of the general formula III, in which Z 1 represents a nucleofugic leaving group is preferably carried out in a solvent such as methylene chloride, acetonitrile, tetrahydrofuran, toluene, acetone or acetone / water, if appropriate in the presence of a base such as potassium carbonate or N-ethyl diisopropylamine at temperatures between -10 and 60 ° C, and
  • a dehydrating or acid-activating agent e.g. in the presence of isobutyl chloroformate, thionyl chloride, trimethylchlorosilane, phosphorus trichloride, N, N '-dicyclohexylcarbodiimide, N, N' -dicyclohexylcarbodiimide / N-hydroxysuccinimide, N, N '-carbonyldiimidazole or N, N' N 'di Triphenylphosphine / carbon tetrachloride or triphenylphosphine / diethyl azodicarboxylate, optionally in the presence of a base such as potassium carbonate, N-ethyl-diisopropylamine or N, N-dimethylamino-pyridine at temperatures between -10 and 60 ° C.
  • a base such as potassium carbonate, N-ethyl-diisopropylamine or N,
  • R 7 is defined as mentioned above, with hydroxylamine or its salts.
  • the reaction is advantageously carried out in a solvent such as methanol, ethanol, n-propanol, water, methanol / water, tetrahydrofuran, tetrahydrofuran / water, dioxane or dioxane / - water, optionally in the presence of a tertiary organic base such as triethylamine at temperatures between 0 and 150 ° C, e.g. at the boiling point of the reaction mixture, but preferably at temperatures between 50 and 100 ° C.
  • a solvent such as methanol, ethanol, n-propanol, water, methanol / water, tetrahydrofuran, tetrahydrofuran / water, dioxane or dioxane / - water
  • a tertiary organic base such as triethylamine
  • the compounds of general formula I obtained can optionally be separated into their enantiomers and / or diastereomers.
  • ice / trans mixtures can be separated into their ice and trans isomers, and compounds with at least one optically active carbon atom can be separated into their enantiomers.
  • the cis / trans mixtures obtained can be chromatographed into their eis and trans isomers, the compounds of general formula I obtained which occur in racemates, according to methods known per se (see Allinger NL and Eliel EL in "Topics in Stereochemistry", Vol. 6, Wiley Interscience, 1971)) in their optical / antipodes and compounds of the general formula I with at least 2 asymmetric carbon atoms on the basis of their physico-chemical differences according to methods known per se, for example by chromatography and / or fractionated crystallization, into their diastereomers which, if in racemic arise form, can then be separated into the enantiomers as mentioned above.
  • the separation of enantiomers is preferably carried out by column separation on chiral phases or by recrystallization from an optically active solvent or by reaction with a salt or derivative such as e.g. Optically active substance which forms esters or amides, in particular acids and their activated derivatives or alcohols, and separation of the diastereomeric salt mixture or derivative thus obtained, e.g. due to different solubilities, it being possible for the free antipodes to be released from the pure diastereomeric salts or derivatives by the action of suitable agents.
  • a salt or derivative such as e.g. Optically active substance which forms esters or amides, in particular acids and their activated derivatives or alcohols
  • optically active alcohols are (+) - or (-) menthol and optically active acyl radicals in amides are, for example, (+) or (-) menthyloxycarbonyl.
  • suitable acids for this are hydrochloric acid, hydrobromic acid, sulfuric acid, methanesulfonic acid, phosphoric acid, fumaric acid, succinic acid, lactic acid, citric acid, tartaric acid or maleic acid.
  • the new compounds of formula I obtained in this way contain a carboxyl group, they can, if desired, subsequently be converted into their salts with inorganic or organic bases, in particular for their pharmaceutical use into their physiologically tolerable salts.
  • inorganic or organic bases for their pharmaceutical use into their physiologically tolerable salts.
  • sodium hydroxide, potassium hydro- xid, arginine, cyclohexylamine, ethanolamine, diethanolamine and triethanolamine for example, sodium hydroxide, potassium hydro- xid, arginine, cyclohexylamine, ethanolamine, diethanolamine and triethanolamine.
  • the new phenylamidines of the general formula I and their salts in particular their physiologically tolerable salts with inorganic or organic acids or bases, have valuable properties.
  • the new phenylamidines of the general formula I and their salts have valuable pharmacological properties, in addition to an anti-inflammatory and bone-depleting effect, in particular antithrombotic, antiaggregatory and tumor or metastasis-inhibiting effects.
  • the new compounds of general formula I according to the invention and their physiologically tolerable salts are suitable for combating or preventing diseases in which smaller or larger cell aggregates occur or cell matrix interactions play a role, e.g. in combating or preventing venous and arterial thromboses, cerebrovascular diseases, pulmonary boluses, heart attacks, arteriosclerosis, osteoporosis and the metastasis of tumors and the therapy of genetically determined or acquired disorders in the interactions of cells with one another or with solid structures.
  • These are also suitable for accompanying therapy for thrombolysis with fibrinolytics or vascular interventions such as transluminal angioplasty or for the therapy of shock conditions, psoriasis, diabetes and inflammation.
  • the concentration of compound A in the plasma is measured 2, 4, 8 and 24 hours after administration of the substance.
  • the rhesus plasma is suspended with a suspension of human platelets in plasma and the compound (3S, 5S) -5- [(4 '-amino-4-biphenylyl) -oxymethyl] -3-carboxymethyl-pyrrolidin-2-one - [3- 3 H-4-biphenylyl] ( 3 H-BIBU 52, described in DE-A-4, 214, 245) as a ligand.
  • the free and bound ligand is separated by centrifugation and quantified by scintillation counting.
  • the concentration of compound A is calculated from the amount of bound ligand using a calibration curve.
  • donor blood is drawn from an anti-cubital vein and anticoagulated with trisodium citrate (final concentration: 13 mmol / 1).
  • the blood is centrifuged at 170 x g for 10 minutes and the supernatant platelet-rich plasma (PRP) is removed.
  • PRP supernatant platelet-rich plasma
  • the residual blood is again centrifuged sharply at 3200 x g and the excess platelet-poor plasma (PPP) is removed.
  • the dose is between 0.1 ⁇ g and 30 mg / kg body weight, preferably 1 ⁇ g to 15 mg / kg body weight, with up to 4 doses per day.
  • the compounds of the formula I prepared according to the invention optionally in combination with other active substances such as thromboxane receptor antagonists and thromboxane synthesis inhibitors or combinations thereof, ADP receptor antagonists, clopidogrel, ticlo pidines, serotonin antagonists, ⁇ receptor antagonists, Al - Kylnitrate such as glycerol trinitrate, phosphodiesterase inhibitors, prostacin and their analogs, fibrinolytics such as tPA, prourokinase, urokinase, streptokinase, or anticoagulants such as heparin, dermatan sulfate, activated protein C, vitamin K antagonists, hirudin or inhibitors of the other activated coagulation factors,
  • (1) is triturated with (3). This trituration is added to the mixture of (2) and (4) with intensive mixing.
  • This powder mixture is filled into size 3 hard gelatin capsules on a capsule filling machine.
  • (1) is triturated with (3). This trituration is added to the mixture of (2) and (4) with intensive mixing.
  • This powder mixture is filled in a size 0 hard gelatin capsule on a capsule filling machine.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP01903646A 2000-01-21 2001-01-13 Substituierte phenylamidine, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung Withdrawn EP1255744A1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10002510 2000-01-21
DE10002510A DE10002510A1 (de) 2000-01-21 2000-01-21 Substituierte Phenylamidine, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
PCT/EP2001/000372 WO2001053280A1 (de) 2000-01-21 2001-01-13 Substituierte phenylamidine, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung

Publications (1)

Publication Number Publication Date
EP1255744A1 true EP1255744A1 (de) 2002-11-13

Family

ID=7628271

Family Applications (1)

Application Number Title Priority Date Filing Date
EP01903646A Withdrawn EP1255744A1 (de) 2000-01-21 2001-01-13 Substituierte phenylamidine, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung

Country Status (8)

Country Link
US (1) US6838460B2 (es)
EP (1) EP1255744A1 (es)
JP (1) JP2003520791A (es)
AU (1) AU2001231676A1 (es)
CA (1) CA2397533A1 (es)
DE (1) DE10002510A1 (es)
MX (1) MXPA02006904A (es)
WO (1) WO2001053280A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3578745B2 (ja) 2002-01-15 2004-10-20 株式会社日立製作所 光経路設定装置、および、光通信網システム
CH695999A5 (de) 2002-02-28 2006-11-15 Wilex Ag Verfahren zur Herstellung von 3- Amidinophenylalanin-Derivaten.
ES2885551T3 (es) * 2014-12-15 2021-12-14 Univ California Agentes antiarrítmicos

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19515500A1 (de) 1995-04-27 1996-10-31 Thomae Gmbh Dr K Substituierte Phenylamidine, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
DE19833105A1 (de) * 1998-07-23 2000-01-27 Boehringer Ingelheim Pharma Substituierte Phenylamidine, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO0153280A1 *

Also Published As

Publication number Publication date
MXPA02006904A (es) 2002-10-23
US20030096824A1 (en) 2003-05-22
WO2001053280A1 (de) 2001-07-26
US6838460B2 (en) 2005-01-04
CA2397533A1 (en) 2001-07-26
DE10002510A1 (de) 2001-07-26
JP2003520791A (ja) 2003-07-08
AU2001231676A1 (en) 2001-07-31

Similar Documents

Publication Publication Date Title
EP0567966B1 (de) Cyclische Iminoderivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
EP0589874B1 (de) Verwendung von (s)(+)-2-äthoxy-4-[n-[1-(2-piperidino-phenyl)-3-methyl-1-butyl]aminocarbonylmethyl]-benzoesäure zur herstellung eines langzeitantidiabetikums
DE4234295A1 (de) Carbonsäurederivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
EP0718287A2 (de) Piperazinderivate, diese Verbindungen enthaltende Arzneimittel, deren Verwendungen und Verfahren zu ihrer Herstellung
EP0608858A1 (de) 5-Gliedrige Heterocyclen als Aggregationshemmer
EP0574808A1 (de) Amidin-Biphenylderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
DE19614204A1 (de) Carbonsäurederivate, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
EP0604800A1 (de) 4- 4- 4-(Carboxyalkyl)-phenyl aminocarbonyl -phenyl -Piperidine als Aggregationshemmer
DE4429079A1 (de) Cyclische Harnstoffderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
DE4326344A1 (de) Carbonamide, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
WO1996004271A1 (de) Kondensierte azepinderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
DE4304650A1 (de) Kondensierte 5-gliedrige Heterocyclen, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
DE19643331A1 (de) 1-(4-Piperidinyl)-piperidinylene, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
EP0567968A1 (de) Cyclische Iminoderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
WO2001047899A1 (de) Substituierte piperazinderivateals inhibitoren des mtp
EP1102746B1 (de) Substituierte phenylamidine mit antithrombotischer wirkung
EP1255744A1 (de) Substituierte phenylamidine, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
EP0824515B1 (de) Substituierte phenylamidine, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
DE4446301A1 (de) Piperazinderivate, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
WO1996002504A1 (de) 6-biphenyloxymethyl-4-carboxy-2-piperidinone, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
WO1995024405A1 (de) Imidazolidin-2-one, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
DE2743493A1 (de) Amine, verfahren zu deren herstellung und sie enthaltende arzneimittel
DE19607436A1 (de) Carbonsäurederivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
WO2000018732A2 (de) Disubstituierte pyrrolidinone, diese verbindungen enthaltende arzneimittel und deren verwendung sowie ihre herstellung
DE19612376A1 (de) Tricyclische Azepinderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20020821

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: BOEHRINGER INGELHEIM PHARMA GMBH & CO.KG

17Q First examination report despatched

Effective date: 20040331

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20050629